Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma (IMvigor130)

April 23, 2024 updated by: Hoffmann-La Roche

A Phase III, Multicenter, Randomized, Placebo-Controlled Study of Atezolizumab (Anti-PD-L1 Antibody) as Monotherapy and in Combination With Platinum-Based Chemotherapy in Patients With Untreated Locally Advanced or Metastatic Urothelial Carcinoma

A Phase III, randomised study of atezolizumab alone and in combination with chemotherapy versus chemotherapy alone in participants with untreated advanced urothelial cancer.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

1213

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
    • New South Wales
      • Macquarie Park, New South Wales, Australia, 2109
        • Macquarie University Hospital
    • Queensland
      • Herston, Queensland, Australia, 4029
        • Royal Brisbane and Women's Hospital
    • South Australia
      • Adelaide, South Australia, Australia, 5112
        • Lyell McEwin Hospital
      • Kurralta Park, South Australia, Australia, 5037
        • Ashford Cancer Center Research
    • Victoria
      • Box Hill, Victoria, Australia, 3128
        • Box Hill Hospital
      • Malvern, Victoria, Australia, 3144
        • Cabrini Medical Centre; Oncology
      • St Albans, Victoria, Australia
        • Sunshine Hospital; Oncology Research
  • Belgium
      • Charleroi, Belgium, 6000
        • GHdC Site Notre Dame
      • Gent, Belgium, 9000
        • AZ Sint Lucas (Sint Lucas)
      • Leuven, Belgium, 3000
        • UZ Leuven Gasthuisberg
      • Liege, Belgium, 4000
        • CHC MontLégia
  • Bosnia and Herzegovina
      • Banja Luka, Bosnia and Herzegovina, 78000
        • University Clinical Centre of the Republic of Srpska
      • Sarajevo, Bosnia and Herzegovina, 71000
        • Clinical Center University of Sarajevo
  • Brazil
    • MG
      • Belo Horizonte, MG, Brazil, 31190-131
        • Hospital Luxemburgo; Oncologia
      • Uberaba, MG, Brazil, 38082-049
        • CETUS Hospital Dia Oncologia
    • RJ
      • Rio De Janeiro, RJ, Brazil, 22290-160
        • Clinicas Oncologicas Integradas - COI
    • RS
      • Ijui, RS, Brazil, 98700-000
        • Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
      • Porto Alegre, RS, Brazil, 90610-000
        • Hospital Sao Lucas - PUCRS
      • Porto Alegre, RS, Brazil, 90035-903
        • Hospital das Clinicas - UFRGS
      • Porto Alegre, RS, Brazil, 90040-373
        • Hospital Nossa Senhora Da Conceicao
      • Santa Maria, RS, Brazil, 97015-373
        • Clinica Viver
    • SC
      • Itajai, SC, Brazil, 88301-220
        • Clinica de Neoplasias Litoral
    • SP
      • Sao Jose do Rio Preto, SP, Brazil, 15090-000
        • Hospital de Base de Sao Jose do Rio Preto
      • Sao Paulo, SP, Brazil, 01246-000
        • Instituto do Cancer do Estado de Sao Paulo - ICESP
      • São Paulo, SP, Brazil, 01321-00
        • Beneficencia Portuguesa de Sao Paulo
  • Canada
    • Alberta
      • Calgary, Alberta, Canada, T2N 4N2
        • Tom Baker Cancer Centre-Calgary; Clinical Research Unit
      • Edmonton, Alberta, Canada, T6G 1Z2
        • Cross Cancer Institute
    • British Columbia
      • Kelowna, British Columbia, Canada, V1Y 5L3
        • BC Cancer Agency, CSI
    • New Brunswick
      • Moncton, New Brunswick, Canada, E1C 8X3
        • Dr. Georges L. Dumont University Hospital Centre
    • Ontario
      • Hamilton, Ontario, Canada, L8V 5C2
        • Juravinski Cancer Clinic; Clinical Trials Department
      • Oshawa, Ontario, Canada, L1G 2B9
        • Lakeridge Health Center; R. S. MacLaughlin Durham Regional Cancer Center
      • Toronto, Ontario, Canada, M2J 1V1
        • North York General Hospital
  • Chile
      • Recoleta, Chile, 8420383
        • Bradford Hill Centro de Investigaciones Clinicas
      • Santiago, Chile, 7500921
        • Fundacion Arturo Lopez Perez
      • Santiago, Chile, 7500713
        • OrlandiOncología
      • Vitacura, Chile, 7650568
        • Clínica Alemana
  • China
      • Beijing, China, 100050
        • Beijing Friendship Hospital
      • Beijing City, China, 100032
        • Peking Union Medical College Hospital
      • Chongqing, China, 400030
        • Chongqing Cancer Hospital
      • Guangzhou, China, 510000
        • Sun Yat-sen Memorial Hospital
      • Nanjing City, China, 211100
        • Jiangsu Cancer Hospital
      • Shanghai, China, 200032
        • Zhongshan Hospital Fudan University
      • Shanghai, China, 200040
        • Huadong Hospital Affiliated to Fudan University
      • Shanghai City, China, 200120
        • Fudan University Shanghai Cancer Center
      • Tianjin, China, 201203
        • The 2nd Hospital of Tianjin Medical University
  • Czechia
      • Brno, Czechia, 656 53
        • Masarykuv onkologicky ustav
      • Olomouc, Czechia, 779 00
        • Fakultni nemocnice Olomouc; Onkologicka klinika
      • Praha 2, Czechia, 128 08
        • Vseobecna Fakultni Nemocnice V Praze
      • Praha 5, Czechia, 15006
        • University Hospital Motol; Department of Urology
  • Estonia
      • Tallinn, Estonia, 13419
        • North Estonia Medical Centre Foundation; Oncology Center
      • Tallinn, Estonia, 10138
        • East Tallinn Central Hospital
  • Finland
      • Oulu, Finland, 90029
        • Oulu University Hospital; Oncology
      • Turku, Finland, 20520
        • Turku Uni Central Hospital; Oncology Clinics
  • Georgia
      • Tbilisi, Georgia, 0186
        • Chemotherapy and Immunotherapy Clinic Medulla
      • Tbilisi, Georgia, 0112
        • Research institute for Clinical Medicine
      • Tbilisi, Georgia, 0144
        • National Center of Urology
  • Greece
      • Athens, Greece, 115 28
        • Alexandras General Hospital of Athens; Oncology Department
      • Patras, Greece, 265 04
        • University Hospital of Patras Medical Oncology
  • Hong Kong
      • Hong Kong, Hong Kong
        • Princess Margaret Hospital; Oncology
      • Hong Kong, Hong Kong
        • Queen Mary Hospital; Dept. of Clinical Oncology
      • Hong Kong, Hong Kong
        • Queen Elizabeth Hospital; Clinical Oncology
      • N.t., Hong Kong
        • The Chinese University of Hong Kong; Department of Clinical Oncology
  • Israel
      • Haifa, Israel, 3109601
        • Rambam Health Care Campus; Oncology
  • Italy
    • Campania
      • Napoli, Campania, Italy, 80131
        • Azienda Ospedaliera A. Cardarelli; Dip. Oncopneumoematologico
    • Emilia-Romagna
      • Meldola, Emilia-Romagna, Italy, 47014
        • IRST Istituto Scientifico Romagnolo Per Lo Studio E Cura Dei Tumori, Sede Meldola; Oncologia Medica
      • Modena, Emilia-Romagna, Italy, 41124
        • A.O. Universitaria Policlinico Di Modena; Oncologia
    • Lazio
      • Roma, Lazio, Italy, 00161
        • Policlinico Umberto i di Roma; dip. Scienze Radiologiche, Oncologiche, Anatomopatologiche
    • Liguria
      • Genova, Liguria, Italy, 16132
        • Az. Osp. Uni Ria San Martino; Cliniche Uni Rie Convenzionate U.O. Oncologia Medical
    • Lombardia
      • Cremona, Lombardia, Italy, 26100
        • ASST DI CREMONA; Dip. Medicina - S.C. Oncologia
      • Milano, Lombardia, Italy, 20133
        • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 2
      • Rozzano, Lombardia, Italy, 20089
        • Istituto Clinico Humanitas;U.O. Oncologia Medica Ed Ematologia
    • Piemonte
      • Torino, Piemonte, Italy, 10126
        • A.O CITTA' DELLA SALUTE E DELLA SCIENZA D. - Presidio San Lazzaro; Oncologia medica 2
    • Puglia
      • San Giovanni Rotondo, Puglia, Italy, 71013
        • IRCCS Ospedale Casa Sollievo Della Sofferenza; Oncologia
    • Toscana
      • Arezzo, Toscana, Italy, 52100
        • Azienda USL8 Arezzo-Presidio Ospedaliero 1 San Donato;U.O.C. Oncologia
    • Umbria
      • Terni, Umbria, Italy, 05100
        • Azienda Ospedaliera S. Maria - Terni; Oncologia
    • Veneto
      • Padova, Veneto, Italy, 35128
        • IRCCS Istituto Oncologico Veneto (IOV); Oncologia Medica Prima
  • Japan
      • Aichi, Japan, 466-8560
        • Nagoya University Hospital
      • Aomori, Japan, 036-8563
        • Hirosaki University Hospital
      • Ehime, Japan, 791-0280
        • National Hospital Organization Shikoku Cancer Center
      • Gunma, Japan, 371-8511
        • Gunma University Hospital
      • Hokkaido, Japan, 003-0804
        • National Hospital Organization Hokkaido Cancer Center
      • Ibaraki, Japan, 305-8576
        • University of Tsukuba Hospital
      • Ishikawa, Japan, 920-8641
        • Kanazawa University Hospital
      • Kumamoto, Japan, 860-8556
        • Kumamoto University Hospital
      • Niigata, Japan, 951-8520
        • Niigata University Medical & Dental Hospital
      • Osaka, Japan, 589-8511
        • Kindai University Hospital
      • Osaka, Japan, 545-8586
        • Osaka Metropolitan university Hospital
      • Tokyo, Japan, 160-8582
        • Keio University Hospital
      • Tokyo, Japan, 105-8470
        • Toranomon Hospital
      • Tokyo, Japan, 135-8550
        • The Cancer Institute Hospital, JFCR; Urology
  • Korea, Republic of
      • Daegu, Korea, Republic of, 41404
        • Kyungpook National University Medical Center
      • Incheon, Korea, Republic of, 21565
        • Gachon University Gil Medical Center
      • Seoul, Korea, Republic of, 03080
        • Seoul National University Hospital
      • Seoul, Korea, Republic of, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Korea, Republic of, 05505
        • Asan Medical Center
      • Seoul, Korea, Republic of, 02841
        • Korea University Anam Hospital
      • Seoul, Korea, Republic of, 06351
        • Samsung Medical Center
  • Malaysia
    • FED. Territory OF Kuala Lumpur
      • Kuala Lumpur, FED. Territory OF Kuala Lumpur, Malaysia, 50586
        • Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi
      • Kuala Lumpur, FED. Territory OF Kuala Lumpur, Malaysia, 59100
        • University Malaya Medical Centre; Clinical Oncology Unit,
  • Mexico
      • Mexico CITY (federal District), Mexico, 02710
        • IMSS Hospital General de Zona No. 48 S. Pedro Xalpa; Departamento de Urología
    • Jalisco
      • Zapopan, Jalisco, Mexico, 45040
        • Consultorio Médico
    • Mexico CITY (federal District)
      • Cdmx, Mexico CITY (federal District), Mexico, 03100
        • Health Pharma Professional Research
    • Nuevo LEON
      • Monterrey, N.L, Nuevo LEON, Mexico, 64710
        • Hospital San Jose; Centro de investigacion y transferencia en salud del Tec de Monterrey
    • Queretaro
      • Querétaro, Queretaro, Mexico, 76090
        • Cancerología
  • Netherlands
      • Den-Haag, Netherlands, 2545 AA
        • Hagaziekenhuis, locatie Leyweg
      • Groningen, Netherlands, 9728 NT
        • Martini Ziekenhuis; Dept of Internal Medicine
      • Sittard-Geleen, Netherlands, 6162 BG
        • Zuyderland Medisch Centrum; Internal Diseases
      • Zwolle, Netherlands, 8025 AB
        • Isala Klinieken, Sophia
  • Poland
      • Bialystok, Poland, 15-027
        • Bialostockie Centrum Onkologii; Oddzial Onkologii Klinicznej
      • Konin, Poland, 62-500
        • Przychodnia Lekarska KOMED, Roman Karaszewski
      • Kraków, Poland, 31-501
        • Szpital Uniwersytecki w Krakowie; Oddzial Kliniczny Onkologii i Poradnia Onkologiczna
      • Lodz, Poland, 93-513
        • Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii
      • Poznan, Poland, 60-569
        • Oddzial Chemioterapii Szpitala Klinicznego Nr 1 w Poznaniu
      • Tomaszów Mazowiecki, Poland, 97-200
        • NU-MED Centrum Diagnostyki i Terapii Onkologicznej
      • Warszawa, Poland, 04-073
        • Szpital Grochowski im. dr med. Rafa?a Masztaka Sp. z o.o.
      • Wroclaw, Poland, 50-556
        • Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego; Oddzial Urologii i Onkologii
  • Portugal
      • Lisboa, Portugal, 1649-035
        • Hospital de Santa Maria; Servico de Oncologia Medica
      • Porto, Portugal, 4200-072
        • IPO do Porto; Servico de Oncologia Medica
  • Romania
      • Baia Mare, Romania, 430031
        • Spitalul Judetean de Urgenta Dr Constantin Opris
      • Bucharest, Romania, 022338
        • Institute Of Oncology Bucharest; Medical Oncology
      • Craiova, Romania, 200347
        • Oncology Center Sf. Nectarie
  • Russian Federation
      • Ivanovo, Russian Federation, 153040
        • Ivanovo Regional Oncology Dispensary
    • Altaj
      • Barnaul, Altaj, Russian Federation, 656049
        • ALTAI REGIONAL ONCOLOGICAL CENTER; "Nadezhda" Clinic
    • Baskortostan
      • UFA, Baskortostan, Russian Federation, 450000
        • SBEI of HPE ?Bashkir State Medical University? of MoH RF
    • Krasnodar
      • Krasnoyarsk, Krasnodar, Russian Federation, 660133
        • Krasnoyarsk Regional Oncology Dispensary n.a. Krizhanovsky; Chemotherapy
    • Moskovskaja Oblast
      • Moscow, Moskovskaja Oblast, Russian Federation, 115478
        • Blokhin Cancer Research Center; Urological Dept
      • Moscow, Moskovskaja Oblast, Russian Federation, 117997
        • Russian Scientific Center of Roentgenoradiology
      • Moscow, Moskovskaja Oblast, Russian Federation, 125248
        • P.A. Herzen Oncological Inst. ; Oncology
    • Niznij Novgorod
      • Nizhny Novgorod, Niznij Novgorod, Russian Federation, 603001
        • Privolzhsk Regional Medical Center
    • Sankt Petersburg
      • Sankt-peterburg, Sankt Petersburg, Russian Federation, 197022
        • SBEI HPE "The First St.Petersburg State Medical University n.a. acad. I.P.Pavlova"of MoH of RF
      • St. Petersburg, Sankt Petersburg, Russian Federation, 197758
        • Scientific Research Oncology Institute named after N.N. Petrov; Oncology
    • Sverdlovsk
      • Yekaterinburg, Sverdlovsk, Russian Federation, 620102
        • Sverdlovsk Regional Clinical Hospital 1
  • Serbia
      • Belgrade, Serbia, 11000
        • Clinical Center of Serbia; Clinic of Urology
      • Nis, Serbia, 18000
        • Clinical Centre Nis, Clinic for Oncology
      • Sremska Kamenica, Serbia, 21204
        • Oncology Institute of Vojvodina
  • Singapore
      • Singapore, Singapore, 119228
        • National University Hospital; National University Cancer Institute, Singapore (NCIS)
      • Singapore, Singapore
        • Oncocare Cancer Centre; Gleneagles Medical Centre
      • Singapore, Singapore, 168583
        • National Cancer Centre; Medical Oncology
  • Slovenia
      • Ljubljana, Slovenia, 1000
        • Institute of Oncology Ljubljana
  • South Africa
      • George, South Africa, 6530
        • GVI Oncology Outeniqua Unit
      • Port Elizabeth, South Africa, 6045
        • Cancercare
      • Pretoria, South Africa, 0001
        • Wilgers Oncology Centre
      • Pretoria, South Africa, 0002
        • Steve Biko Academic Hospital; Oncology
      • Sandton, South Africa, 2196
        • Sandton Oncology Medical Group
  • Spain
      • Albacete, Spain, 02006
        • Complejo Hospitalario Universitario de Albacete; Servicio de Oncologia
      • Barcelona, Spain, 08041
        • Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia
      • Barcelona, Spain, 08036
        • Hospital Clinic de Barcelona. Unidad de Nuevas Terapias;Oncology Department
      • Burgos, Spain, 09006
        • Complejo Asistencial Universitario De Burgos; Servicio de Oncologia
      • Caceres, Spain, 10003
        • Hospital San Pedro De Alcantara; Servicio de Oncologia
      • Granada, Spain, 18014
        • Hospital Universitario Virgen de las Nieves; Servicio de Oncologia
      • Huelva, Spain, 21005
        • Hospital Juan Ramon Jimenez;Servicio de Oncologia
      • Jaen, Spain, 23007
        • Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico; Servicio de Oncologia
      • Leon, Spain, 24071
        • Complejo Asistencial Universitario de Leon; Servicio de Oncologia
      • Lugo, Spain, 27003
        • Hospital Universitario Lucus Augusti
      • Madrid, Spain, 28034
        • Hospital Ramon y Cajal; Servicio de Oncologia
      • Madrid, Spain, 28041
        • Hospital Universitario 12 de Octubre; Servicio de Oncologia
      • Madrid, Spain, 28040
        • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
      • Madrid, Spain, 28007
        • Hospital General Universitario Gregorio Marañon; Servicio de Oncologia
      • Madrid, Spain, 28046
        • Hospital Universitario La Paz; Servicio de Oncologia
      • Sevilla, Spain, 41013
        • Hospital Universitario Virgen del Rocio; Servicio de Oncologia
      • Toledo, Spain, 45007
        • Hospital Universitario de Toledo
      • Valencia, Spain, 46026
        • Hospital Universitario la Fe; Servicio de Oncologia
      • Zaragoza, Spain, 50009
        • Hospital Universitario Miguel Servet; Servicio de Oncologia Medica
      • Zaragoza, Spain, 50009
        • Hospital Clinico Universitario Lozano Blesa; Servicio de Oncologia
    • Alicante
      • Elche, Alicante, Spain, 03203
        • Hospital General Universitario de Elche; Servicio de Oncologia
    • Barcelona
      • Badalona, Barcelona, Spain, 08916
        • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
      • Badalona, Barcelona, Spain, 08916
        • Institutio Catalan De Oncologia
      • Manresa, Barcelona, Spain, 08243
        • Complejo Hospitalario de Althaia; Servicio de Oncologia
      • Sabadell, Barcelona, Spain, 8208
        • Corporacio Sanitaria Parc Tauli; Servicio de Oncologia
      • Sant Andreu de La Barca, Barcelona, Spain, 08740
        • Hospital Univ Vall d'Hebron; Servicio de Oncologia
    • Cantabria
      • Santander, Cantabria, Spain, 39008
        • Hospital Universitario Marques de Valdecilla; Servicio de Oncologia
    • Castellon
      • Castellon de La Plana, Castellon, Spain, 12002
        • Hospital Provincial de Castellon; Servicio de Oncologia
    • Cordoba
      • Córdoba, Cordoba, Spain, 14004
        • Hospital Universitario Reina Sofia; Servicio de Oncologia
    • Islas Baleares
      • Palma De Mallorca, Islas Baleares, Spain, 07014
        • Hospital Universitario Son Espases
    • Navarra
      • Pamplona, Navarra, Spain, 31008
        • Clinica Universitaria de Navarra; Servicio de Oncologia
    • Pontevedra
      • Vigo, Pontevedra, Spain, 36312
        • Hospital Alvaro Cunqueiro
    • Vizcaya
      • Bilbao, Vizcaya, Spain, 48013
        • Hospital de Basurto; Servicio de Oncologia
  • Taiwan
      • Kaohisung, Taiwan, 833
        • Chang Gung Medical Foundation - Kaohsiung; Oncology
      • Taichung, Taiwan, 40447
        • China Medical University Hospital; Urology
      • Taichung, Taiwan, 407
        • Taichung Veterans General Hospital; Division of Urology
      • Tainan, Taiwan, 704
        • National Cheng Kung Uni Hospital; Dept of Hematology and Oncology
      • Taipei, Taiwan, 100
        • National Taiwan Uni Hospital; Dept of Oncology
      • Taoyuan, Taiwan, 333
        • Chang Gung Medical Foundation-Linkou, Urinary Oncology
  • Thailand
      • Bangkok, Thailand, 10330
        • Chulalongkorn Hospital; Medical Oncology
      • Bangkok, Thailand, 10700
        • Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology
      • Bangkok, Thailand, 10400
        • Ramathibodi Hospital; Dept of Med.-Div. of Med. Onc
      • Bangkok, Thailand, 10300
        • Vajira Hospital
      • ChiangMai, Thailand, 50200
        • Maharaj Nakorn Chiang Mai Hospital; Department of Medicine
  • Turkey
      • Adana, Turkey, 01230
        • Baskent University Adana Dr. Turgut Noyan Practice and Research Hospital; Medical Oncology
      • Ankara, Turkey, 06490
        • Ankara Bilkent City Hospital
      • Edirne, Turkey, 22030
        • Trakya Universitesi Tip Fakultesi, Medikal Onkoloji Bilim Dali, Balkan Yerleskesi
      • Istanbul, Turkey, 34093
        • Bezmi Alem Vakif University Medical School; Oncology
      • Istanbul, Turkey, 34098
        • Istanbul University Cerrahpa?a-Cerrahpa?a Medical Faculty; Medikal Onkoloji Departmani
      • Kadiköy, Turkey, 34722
        • Goztepe Prof.Dr. Suleyman Yalcin City Hospital; Clinical Oncology
      • Kar??yaka, Turkey, 35575
        • Medikal Park Izmir Hospital
      • Samsun, Turkey, 55139
        • 19 Mayis University Medical Faculty; Medical Oncology Department
      • Sihhiye/Ankara, Turkey, 06230
        • Hacettepe Uni Medical Faculty Hospital; Oncology Dept
  • Ukraine
      • Dnipropetrovsk, Ukraine, 49102
        • CI Dnipropetrovsk CMCH #4 MA of MOHU Ch of Oncology and MR
      • Zaporizhzhia, Ukraine, 69600
        • Zaporizhzhia Regional Clinic
    • Kharkiv Governorate
      • Kharkiv, Kharkiv Governorate, Ukraine, 61037
        • Regional Clinical Center of Urology and Nephrology n.a. V.I. Shapoval Department of Urology #4
  • United Kingdom
      • Glasgow, United Kingdom, G12 0YN
        • Beatson West of Scotland Cancer Centre
      • London, United Kingdom, NW1 2PG
        • University College London Hospitals NHS Foundation Trust - University College Hospital
      • Manchester, United Kingdom, M20 4BX
        • The Christie NHS Foundation Trust
      • York, United Kingdom, YO31 8HE
        • The York Hospital
  • United States
    • Arkansas
      • Springdale, Arkansas, United States, 72762
        • Highlands Oncology Group
    • California
      • San Luis Obispo, California, United States, 93401
        • Coastal Integrative Cancer Care
    • Connecticut
      • New Haven, Connecticut, United States, 06510-3206
        • Yale School of Medicine
      • Norwalk, Connecticut, United States, 06856
        • Norwalk Hospital
    • Delaware
      • Newark, Delaware, United States, 18713
        • Christina Care Institutional Review Board
    • Florida
      • Fort Myers, Florida, United States, 33901-8101
        • Florida Cancer Specialists; Department of Oncology
      • Orlando, Florida, United States, 32824
        • UF Health Cancer Center at Orlando Health
      • Saint Petersburg, Florida, United States, 33705
        • Florida Cancer Specialists (St. Petersburg ? St. Anthony?s Professional Building)
      • Tampa, Florida, United States, 33612
        • Moffitt Cancer Center; GME Office
    • Illinois
      • Chicago, Illinois, United States, 60637
        • The University of Chicago Biological Sciences; Dept. of Medicine, Section of Hematology/Oncology
    • Indiana
      • Fort Wayne, Indiana, United States, 46845
        • Parkview Research Center
    • Kentucky
      • Louisville, Kentucky, United States, 40202
        • Norton Cancer Institute
    • Louisiana
      • Metairie, Louisiana, United States, 70006
        • East Jefferson Hematology Oncology; Hematology Oncology-Yenni Pavillion
    • Minnesota
      • Saint Louis Park, Minnesota, United States, 55426
        • Park Nicollet Clin-Cancer Ctr
    • Nevada
      • Las Vegas, Nevada, United States, 89128
        • Comprehensive Cancer Centers of Nevada
    • New York
      • New York, New York, United States, 10065
        • Memorial Sloan Kettering Cancer Center
      • New York, New York, United States, 10029
        • Mount Sinai School of Medicine - Tisch Cancer Institute
    • North Carolina
      • Chapel Hill, North Carolina, United States, 27599
        • University of North Carolina, Lineberger Cancer Ctr
    • South Carolina
      • Greenville, South Carolina, United States, 29607
        • Bon Secours - St. Francis Hospital
    • Tennessee
      • Germantown, Tennessee, United States, 38138
        • Sarah Cannon Research Institute / Tennessee Oncology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria

  • Considered to be eligible to receive platinum-based chemotherapy, in the investigator's judgment
  • Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to (</=) 2
  • Histologically documented, locally advanced (T4b, any N; or any T, N2-3) or metastatic urothelial carcinoma (mUC) (M1, Stage IV) (also termed transitional cell carcinoma [TCC] or urothelial cell carcinoma [UCC] of the urinary tract; including renal pelvis, ureters, urinary bladder, and urethra)
  • Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens in paraffin blocks (blocks preferred) or at least 15 unstained slides, with an associated pathology report, for central testing and determined to be evaluable for tumor PD-L1 expression prior to study enrollment; participants who have fewer than 15 unstained slides available at baseline (but no less than [<] 10) may be eligible following discussion with the Medical Monitor
  • No prior chemotherapy for inoperable locally advanced or mUC
  • For participants who received prior adjuvant/neoadjuvant chemotherapy or chemo-radiation for urothelial carcinoma, a treatment-free interval more than (>) 12 months between the last treatment administration and the date of recurrence is required in order to be considered treatment naive in the metastatic setting
  • Prior local intravesical chemotherapy or immunotherapy is allowed if completed at least 4 weeks prior to the initiation of study treatment
  • Measurable disease, as defined by RECIST v1.1
  • Adequate hematologic and end-organ function
  • For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of <1% per year during the treatment period and for at least 6 months after the last dose of carboplatin, cisplatin, or gemcitabine or for 5 months after the last dose of atezolizumab
  • For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from donating sperm

Exclusion Criteria:

  • Any approved anti-cancer therapy, including chemotherapy or hormonal therapy, within 3 weeks prior to initiation of study treatment
  • Treatment with any other investigational agent or participation in another clinical study with therapeutic intent within 28 days prior to enrolment
  • Active or untreated CNS metastases as determined by computed tomography (CT) or magnetic resonance imaging evaluation during screening and prior radiographic assessments
  • Participants with treated asymptomatic central nervous system (CNS) metastases are eligible, provided they meet all of the following criteria: * Evaluable or measurable disease outside the CNS * No metastases to midbrain, pons, medulla, or within 10 mm of the optic apparatus (optic nerves and chiasm) * No history of intracranial or spinal cord hemorrhage * No ongoing requirement for corticosteroid as therapy for CNS disease; anti-convulsants at a stable dose are allowed * No evidence of significant vasogenic edema * No stereotactic radiation, whole-brain radiation or neurosurgical resection within 4 weeks prior to Cycle 1, Day 1 * Radiographic demonstration of interim stability (i.e., no progression) between the completion of CNS-directed therapy and the screening radiographic study * Screening CNS radiographic study >/=4 weeks since completion of radiotherapy or surgical resection and >/=2 weeks since discontinuation of corticosteroids
  • Prior treatment with CD137 agonists, anti-CTLA-4, anti-programmed death-1 (PD-1), or anti-PD-L1 therapeutic antibody or pathway-targeting agents
  • Treatment with systemic corticosteroids or other systemic immunosuppressive medications (including but not limited to prednisone, dexamethasone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [TNF] agents) within 2 weeks prior to Cycle 1, Day 1 or anticipated requirement for systemic immunosuppressive medications during the study
  • Leptomeningeal disease
  • Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
  • Uncontrolled tumour-related pain or hypercalcemia
  • Significant cardiovascular disease including known left ventricular ejection fraction (LVEF) <40%
  • Severe infections within 4 weeks before randomization or therapeutic oral or IV antibiotics within 2 weeks before randomization
  • Major surgical procedure within 4 weeks prior to randomization or anticipation of need for a major surgical procedure during the course of the study other than for diagnosis
  • Malignancies other than urothelial carcinoma within 5 years prior to Cycle 1, Day 1
  • Life expectancy of <12 weeks
  • Pregnant or lactating, or intending to become pregnant during the study
  • Serum albumin <25 gram per liter (g/L)
  • History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins
  • Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation
  • History of autoimmune disease
  • Participants with prior allogeneic stem cell or solid organ transplantation
  • History of idiopathic pulmonary fibrosis (including pneumonitis), drug-induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest CT scan
  • Positive test for human immunodeficiency virus (HIV)
  • Active hepatitis B or hepatitis C
  • Active tuberculosis
  • Administration of a live, attenuated vaccine within 4 weeks before Cycle 1, Day 1

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Atezolizumab+Gemcitabine+Carboplatin/Cisplatin
Participants will receive blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Drug: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Other Names:
  • Tecentriq
Drug: Carboplatin
Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Drug: Gemcitabine
Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Drug: Cisplatin
Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Placebo Comparator: Placebo+Gemcitabine+Carboplatin/Cisplatin
Participants will receive blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).
Drug: Carboplatin
Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Drug: Gemcitabine
Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Drug: Cisplatin
Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
Other: Placebo
Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Experimental: Atezolizumab Monotherapy
Eligible participants will receive open-label atezolizumab as monotherapy.
Drug: Atezolizumab
Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
Other Names:
  • Tecentriq

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)
Overall Survival (OS) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline until death due to any cause (up to approximately 73 months)
OS is defined as the time from randomization to death due to any cause.
Baseline until death due to any cause (up to approximately 73 months)
Overall Survival (OS) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline until death due to any cause (up to approximately 73 months)
OS is defined as the time from randomization to death due to any cause.
Baseline until death due to any cause (up to approximately 73 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Objective Response Rate (ORR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments >= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Objective Response Rate (ORR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Objective response rate (ORR) is defined as the proportion of participants with a confirmed objective response, either complete response (CR) or partial response (PR), observed on two assessments >= 28 days apart per RECIST v1.1, based on investigator assessment. The analysis population for ORR will be all randomized participants with measurable disease at baseline.
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of Response (DOR) in Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of Response (DOR) in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
Duration of response (DOR) is defined for participants with an objective response as the time from the first documented objective response to documented disease progression per RECIST v1.1, based on investigator assessment, or death due to any cause, whichever occurs first.
From first documented objective response (CR or PR) to disease progression, death, or loss of follow-up, whichever occurs first (up to approximately 73 months)
IRF-PFS
Time Frame: Randomization to first documented disease progression or death from any cause (up to 35 months)
Independent review facility PFS (IRF-PFS) is defined as the time from randomization to the first documented disease progression as determined by blinded independent central review with use of RECIST v1.1, or death due to any cause, whichever occurs first.
Randomization to first documented disease progression or death from any cause (up to 35 months)
OS Event Free Rate Atezolizumab+Gemcitabine+Carboplatin/Cisplatin Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Year 1
Overall Survival (OS) Event Free Rate at 1 Year.
Year 1
OS Event Free Rate in Atezolizumab Monotherapy Arm Versus Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Year 1
Overall Survival (OS) Event Free Rate at 1 Year.
Year 1
PFS Event Free Rate
Time Frame: Year 1
Progression Free Survival (PFS) Event Free Rate at Year 1
Year 1
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Up to approximately 73 months
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Up to approximately 73 months
Time to Deterioration in Global Health Status as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Time Frame: Up to approximately 73 months
Time to deterioration in global health status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 in the Placebo+Chemo Arm versus Atezolizumab Monotherapy Arm.
Up to approximately 73 months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Up to approximately 73 months
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm.
Up to approximately 73 months
Time to Deterioration in Physical Function as Measured by the EORTC QLQ-C30 Score in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab Monotherapy Arm
Time Frame: Up to approximately 73 months
Median time to deterioration in physical function as measured by the QLQ-C30 in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm versus Atezolizumab Monotherapy Arm.
Up to approximately 73 months
Maximum Atezolizumab Serum Concentration
Time Frame: Cycle 1 Day 1
Maximum atezolizumab serum concentration.
Cycle 1 Day 1
Minimum Atezolizumab Serum Concentration
Time Frame: Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Minimum atezolizumab serum concentration.
Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 16 Day 1, Cycle 24 Day 1, Cycle 32 Day 1, Day 120 post dose of last blinded atezolizumab treatment, and study drug early discontinuation
Percentage of Participants With Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs)
Time Frame: Up to approximately 35 months
Percentage of participants with Anti-Therapeutic (Anti-Atezolizumab) Antibodies (ATAs).
Up to approximately 35 months
Investigator-Assessed Progression-Free Survival (INV-PFS) in Participants Treated With Atezolizumab Monotherapy Arm Compared With Placebo+Gemcitabine+Carboplatin/Cisplatin Arm
Time Frame: Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.
Baseline up to disease progression, death, or loss of follow-up, whichever occurs first (assessed at baseline, every 9 weeks for 54 weeks and every 12 weeks thereafter up to 35 months)
Percentage of Participants With Adverse Events (AEs) Assessed Using National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
Time Frame: Baseline up to 90 months
Baseline up to 90 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Hoffmann-La Roche

Investigators

  • Study Director: Clinical Trials, Hoffmann-La Roche

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 30, 2016

Primary Completion (Actual)

August 31, 2022

Study Completion (Actual)

February 12, 2024

Study Registration Dates

First Submitted

June 17, 2016

First Submitted That Met QC Criteria

June 20, 2016

First Posted (Estimated)

June 21, 2016

Study Record Updates

Last Update Posted (Actual)

April 29, 2024

Last Update Submitted That Met QC Criteria

April 23, 2024

Last Verified

April 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • WO30070
  • 2016-000250-35 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Urothelial Carcinoma

Clinical Trials on Atezolizumab

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe